Hong Kong · Delayed Price · Currency is HKD InnoCare Pharma Earnings Call Transcripts
Fiscal Year 2025
-
Achieved first annual profit and 135% revenue growth in 2025, driven by strong product sales, BD deals, and pipeline progress. Outlook for 2026 includes >35% drug sales growth, major NDA submissions, and continued R&D investment, supported by robust cash reserves.
-
Revenue grew 74.3% year-over-year in H1 2025, driven by strong drug sales and new approvals. Net loss narrowed by 86.7%, and the company maintains a robust cash position to support global R&D and commercialization. Multiple late-stage assets and strategic partnerships are set to drive future growth.
Fiscal Year 2024
-
Orelabrutinib sales grew 49.1% year-over-year, driving a 30% reduction in annual loss and strong cash reserves. Multiple late-stage assets advanced, including NDAs for CLL/SLL and Tafasitamab, while the ADC platform and TYK2 inhibitors showed promising progress.
-
Q3 2024 saw robust revenue growth, margin improvement, and a narrowed loss, driven by orelabrutinib's strong performance and expanded clinical pipeline. Guidance for full-year sales growth was raised, with continued investment in R&D and commercialization.
-
Strong H1 2024 revenue growth was driven by orelabrutinib, with improved margins and reduced losses. Multiple clinical and regulatory milestones were achieved, and robust cash reserves support long-term growth, with break-even targeted by 2027–2028.